IRF5 and systemic lupus erythematosus: We used plasma from SLE patients with active or inactive disease, as recently described (25), and from healthy donors that carry either the homozygous IRF5-SLE haplotype that is a risk factor for SLE, or the homozygous non-risk haplotype, to assess the sensitivity and range of plasma NET detection.